Skip to main content

Table 2 Treatment response of SR aGVHD between the two groups at day 28

From: Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial

Outcomes

MSC group

Control group

P

No. of patients

99

99

 

OR rate of aGVHD grade

   

 II

35 (97.2%)

34 (91.9%)

0.317

 III

33 (80.5%)

30 (68.2%)

0.196

 IV

14 (63.6%)

6 (33.3%)

0.057

OR rate of aGVHD involved organs numbers

   

 1

24 (96.0%)

26 (89.7%)

0.375

 》 2

58 (78.4%)

44 (62.9%)

0.002

OR rate of aGVHD organs

   

 Skin

64 (87.7%)

50 (79.4%)

0.190

 Liver

33 (76.7%)

32 (69.6%)

0.446

 Upper GI

9 (100.0%)

9 (90.0%)

0.330

 Lower GI

54 (68.4%)

46 (59.7%)

0.262

OR rate of patients’ age

   

 < 18 year

12 (85.7%)

11 (64.7%)

0.183

 ≥ 18 year

70 (82.4%)

59 (71.9%)

0.109